← All trials
NCT04978272
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 18, 2021
- Primary completion
- Aug 31, 2026
- Completion date
- Aug 31, 2026
- First posted
- Jul 27, 2021
- Last posted
- Sep 17, 2021
- Enrollment
- 924
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of California, San FranciscoLead sponsor
- Infectious Disease Institute, Kampala, UgandaCollaborator
- Stanford UniversityOverall official - principal investigator
- Stanford UniversityCollaborator
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- University of California, San FranciscoSponsor investigator
- Karolinska InstituteCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.